human papillomavirus (HPV) vaccine

August 25, 2021

NIH Awards UAMS’ Nakagawa $3.6 Million to Expand HPV Cancer Vaccine Study

Marty Trieschmann

Dr. Mayumi Nakagawa - With an additional $3.6 million from the National Institutes of Health, Mayumi Nakagawa's, M.D., Ph.D., ground-breaking HPV vaccine research tops $10 million.

Mayumi Nakagawa, M.D., Ph.D., was awarded $3.6 million from the National Cancer Institute (NCI) to complete phase 2 clinical trials of PepCan, a breakthrough vaccine she developed at UAMS to treat cancers caused by human papillomavirus (HPV).

March 9, 2016

UAMS Researcher’s HPV Vaccine Holds Promise for Saving Lives, Preventing Premature Births

David Robinson

LITTLE ROCK — A human papillomavirus (HPV) vaccine, discovered by a University of Arkansas for Medical Sciences (UAMS) researcher and recently shown to be safe, is being made available to a larger group of Arkansas women for further testing. In her recently completed phase I study involving 34 women, researcher Mayumi Nakagawa, M.D., Ph.D., demonstrated…